Dengue Virus Envelope Protein Research Articles

A Viroinformatics Study: B-Cell Polytope Mapping of Envelope Protein to Develop Vaccine Candidate against Four DENV Serotype

Nowadays, dengue virus (DENV) is still become a global problem, even though the virus infection issues have reached half of the population in some countries each year. DENV belongs to the enveloped virus with positive-sense single-stranded RNA (+ssRNA) genus Flavivirus and belongs to the Flaviviridae family. DENV has structural proteins which consist of the envelope protein (E), capsid (C), and membrane (M). There are four serotypes of this virus which are DENV-1, 2, 3, and 4. These four serotypes are transmitted to humans through Aedes sp. The development of this vaccine is still in progress and the challenge of this DENV vaccine candidate design is to overcome the heterotypic infection and the expansion of coverage protection to all virus serotypes. This research uses design simulation for vaccine candidates using B cell epitope in all DENV’s serotypes envelope to trigger the antibody formation through bioinformatics method that consists of protein modeling, immunogenicity, toxicity, and immune stimulation. DENV envelope protein was predicted to have polytope that can be recognized by B cells and act as an antigen, have low similarity with the composing sequence of cell surface receptors on the body, and non-toxic, and then can trigger the population increase of B cell and IgM antibody production with high avidity to neutralize four of the DENV serotypes. We recommend the B cell polytype which consists of A, C, E, and G peptides be examined by the wet-lab approach.

Prediction of B cell epitopes in envelope protein of dengue virus using immunoinformatics approach

Prediction of B cell epitopes in envelope protein of dengue virus using immunoinformatics approach

Unveiling a Shield of Hope: A Novel Multiepitope-Based Immunogen for Cross-Serotype Cellular Defense against Dengue Virus.

Dengue virus (DENV) infection continues to be a public health challenge, lacking a specific cure. Vaccination remains the primary strategy against dengue; however, existing live-attenuated vaccines display variable efficacy across four serotypes, influenced by host serostatus and age, and predominantly inducing humoral responses. To address this limitation, this study investigates a multiepitope-based immunogen designed to induce robust cellular immunity across all DENV serotypes. The chimeric immunogen integrates H-2d specific MHC-I binding T-cell epitopes derived from conserved domains within the DENV envelope protein. Immuno-informatics analyses supported its stability, non-allergenic nature, and strong MHC-I binding affinity as an antigen. To assess the immunogenicity of the multiepitope, it was expressed in murine bone-marrow-derived dendritic cells (BMDCs) that were used to prime mice. In this experimental model, simultaneous exposure to T-cell epitopes from all four DENV serotypes initiated distinct IFNγ-CD8 T-cell responses for different serotypes. These results supported the potential of the multiepitope construct as a vaccine candidate. While the optimization of the immunogen design remains a continuous pursuit, this proof-of-concept study provides a starting point for evaluating its protective efficacy against dengue infection in vivo. Moreover, our results support the development of a multiepitope vaccine that could trigger a pan-serotype anti-dengue CD8 response.

Mutation of conserved histidine residues of dengue virus envelope protein impairs viral like particle maturation and secretion

Dengue virus (DENV) envelope protein plays crucial role in virus entry and maturation of virus during infection. Maturation of DENV occurs in the trans Golgi network at slightly acidic pH which is close to pKa of histidine. When exposed to the acidic environment of the late secretory pathway, dengue virus particles go through a significant conformational change, whereby interactions of structural proteins envelope (E) and prM proteins are reorganised and enable furin protease to cleave prM resulting in mature virus. In order to study the role of histidine of E protein in DENV maturation, we mutated 7 conserved histidine residues of envelope protein and assessed the percent of budding using viral like particle (VLP) system. Histidine mutants; H144A, H244A, H261A and H282A severely disrupted VLP formation without any significant change in expression in cell and its oligomerization ability. Treatment with acidotropic amine reversed the defect for all 4 mutants suggesting that these histidines could be involved in maturation and release. Over expression of capsid protein slightly enhanced VLP release of H244A and H261A. Similarly, furin over expression increased VLP release of these mutants. Co-immunoprecipitation studies revealed that prM and E interaction is lost for H244A, H261A and H282A mutants at acidic pH but not at neutral pH indicating that they could be involved in histidine switch during maturation at acidic pH. Detailed analysis of the mutants could provide novel insights on the interplay of envelop protein during maturation and aid in target for drug development.

In silico comparative structural and functional analysis of dengue virus (Serotypes 1 to 4) envelope protein

In silico comparative structural and functional analysis of dengue virus (Serotypes 1 to 4) envelope protein

Marked enhancement of the immunogenicity of plant-expressed IgG-Fc fusion proteins by inclusion of cholera toxin non-toxic B subunit within the single polypeptide.

Immunoglobulin G (IgG)-based fusion proteins have been widely exploited as a potential vaccine delivery platform but in the absence of exogenous adjuvants, the lack of robust immunity remains an obstacle. Here, we report on a key modification that overcomes that obstacle. Thus, we constructed an IgG-Fc vaccine platform for dengue, termed D-PCF, which in addition to a dengue antigen incorporates the cholera toxin non-toxic B subunit (CTB) as a molecular adjuvant, with all three proteins expressed as a single polypeptide. Following expression in Nicotiana benthamiana plants, the D-PCF assembled as polymeric structures of similar size to human IgM, a process driven by the pentamerization of CTB. A marked improvement of functional properties in vitro and immunogenicity in vivo over a previous iteration of the Fc-fusion protein without CTB [1] was demonstrated. These include enhanced antigen presenting cell binding, internalization and activation, complement activation, epithelial cell interactions and ganglioside binding, as well as more efficient polymerization within the expression host. Following immunization of mice with D-PCF by a combination of systemic and mucosal (intranasal) routes, we observed robust systemic and mucosal immune responses, as well as systemic T cell responses, significantly higher than those induced by a related Fc-fusion protein but without CTB. The induced antibodies could bind to the domain III of the dengue virus envelope protein from all four dengue serotypes. Finally, we also demonstrated feasibility of aerosolization of D-PCF as a prerequisite for vaccine delivery by the respiratory route.

Molecular docking, simulations of animal peptides against the envelope protein of Dengue virus

Peptides are biologically active, small molecules with high specificity in its mode of action that can be effective at nanomolar concentrations. Peptide-based antiviral medicines have already been licensed and used to treat human immunodeficiency virus (HIV), influenza virus and hepatitis C virus. So far, no peptide drug has been approved for antiviral treatment against Dengue virus, and many are under clinical trials. Therefore, developing a reasonable peptide against the Dengue virus Envelope protein structure will be a successful strategy for treating Dengue. Hence, we investigated protein-protein docking interactions between 215 peptides retrieved from the AVP database against the envelope protein using Cluspro and HADDOCK followed by the evaluation of their allegenicity, toxicity and physicochemical characteristics investigation. Further validation of the protein–peptide complexes was performed with Molecular dynamics simulations and Molecular Mechanics Poisson–Boltzmann surface area (MMPBSA) analysis on the hit inhibitors. This study revealed that Indolicidin (−75.026 ± 1.54 KJ/mol) and Human Neutrophil peptide-1 (−71.6551 ± 2.112 KJ/mol) shows higher negative ΔG binding implicating their relative stabilization in the protein–peptide interactions during 100 ns of dynamic simulations. Also, both the peptides exhibited desirable physicochemical properties and were nonallergenic. Hence, we further aim to test these peptides by in vitro and in vivo studies to confirm their efficacy against Dengue virus. Communicated by Ramaswamy H. Sarma

Expanding the synthesis of a library of potent glucuronic acid glycodendrons for Dengue virus inhibition

Multivalent glycodendrons are valuable tools to mimic many structural and functional features of cell-surface glycoconjugates and its focal position scaffolds represent important components to increase specificity and affinity. Previous work in our group described the preparation of a tetravalent glucuronic acid dendron that binds with good affinity to Dengue virus envelope protein (KD = 22 μM). Herein, the chemical synthesis and binding analysis of a new library of potent glucuronic acid dendrons bearing different functional group at the focal position and different level of multivalency are described. Their chemical synthesis was performed sequentially in three stages and with good yields. Namely a) the chemical synthesis of the oligo and polyalkynyl scaffolds, b) assembling with fully protected glucuronic acid-based azide units by using a microwave assisted copper-catalysed azide-alkyne cycloaddition reaction and c) sequential deprotection of hydroxyl and carboxylic acid groups.Surface Plasmon Resonance studies have demonstrated that the valency and the focal position functional group exert influence on the interaction with Dengue virus envelope protein. Molecular modelling studies were carried out in order to understand the binding observed. This work reports an efficient glycodendrons chemical synthesis that provides appropriate focal position functional group and multivalence, that offer an easy and versatile strategy to find new active compounds against Dengue virus.

Polyubiquitin protein of Aedes aegypti as an interacting partner of dengue virus envelope protein.

Dengue virus (DENV) is an arbovirus that comprises four antigenically different serotypes. Aedes aegypti (Diptera: Culicidae) acts as the principal vector for DENV transmission, and vector control is crucial for dengue fever epidemic management. To design effective vector control strategies, a comprehensive understanding of the insect vector and virus interaction is required. Female Ae. aegypti ingests DENV during the acquisition of a blood meal from an infected human. DENV enters the insect midgut, replicates inside it and reaches the salivary gland for transmitting DENV to healthy humans during the subsequent feeding cycles. DENV must interact with the proteins present in the midgut and salivary glands to gain entry and accomplish successful replication and transmission. Ae. aegypti midgut cDNA library was prepared, and yeast two-hybrid screening was performed against the envelope protein domain III (EDIII) protein of DENV-2. The polyubiquitin protein was selected from the various candidate proteins for subsequent analysis. Polyubiquitin gene was amplified, and the protein was purified in a heterologous expression system for in vitro interaction studies. In vitro pull-down assay presented a clear interaction between polyubiquitin protein and EDIII. To further confirm this interaction, a dot blot assay was employed, and polyubiquitin protein was found to interact with DENV particles. Our results enable us to suggest that polyubiquitin plays an important role in DENV infection within mosquitoes.

Structural and functional characterization of Aedes aegypti pupal cuticle protein that controls dengue virus infection.

The pupal cuticle protein from Aedes aegypti (AaPC) inhibits dengue virus (DENV) infection; however, the underlying mechanism of this inhibition remains unknown. Here, we report that AaPC is an intrinsically disordered protein and interacts with domain I/II of the DENV envelope protein via residues Asp59, Asp61, Glu71, Asp73, Ser75, and Asp80. AaPC can directly bind to and cause the aggregation of DENV, which in turn blocks virus infection during the virus-cell fusion stage. AaPC may also influence viral recognition and attachment by interacting with human immune receptors DC-SIGN and CD4. These findings enhance our understanding of the role of AaPC in mitigating viral infection and suggest that AaPC is a potential target for developing inhibitors or antibodies to control dengue virus infection.

In silico screening of plant peptides against the envelope protein of dengue virus.

Peptide therapeutics are found to be an emerging and attractive class of treatment due to their highly specific and safe nature. Hence twenty plant peptides were subjected to screening by molecular docking against the envelope protein of the dengue virus using Clus Pro, Patch Dock, and HADDOCK servers. Physicochemical parameters, allergenicity, and toxicity profile of the plant peptides were estimated by Protparam analysis, AllergenFP, and ToxinPred web servers. Six potential compounds namely Ginkbilobin, Cycloviolin-D, Circulin-B, Circulin-A, Cycloviolacin-013, and Circulin-C showed the highest binding energy with both nonallergenic and nontoxic properties. They also exhibited desirable half-lives extending to 30 hrs except for Ginkbilobin, which showed the least half-life of 4.4 hours and non-polar activity. The residues of Ala-4 of Ginkbilobin; Arg-30 of Cycloviolin D; Arg-29 of Circulin A and C interacted with the Try 101 of the domain II of Envelope protein, implying the possible inhibition of the insertion process of the trimeric E protein during fusion with the host cells. Thus, the identified plant peptides could serve as potential leads upon further subjection to in vitro studies.

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.

Dengue is the most common viral infection spread by mosquitoes, prevalent in tropical countries. The acute dengue virus (DENV) infection is a benign and primarily febrile illness. However, secondary infection with alternative serotypes can worsen the condition, leading to severe and potentially fatal dengue. The antibody raised by the vaccine or the primary infections are frequently cross-reactive; however, weakly neutralizing, and during subsequent infection, they may increase the odds of antibody-dependent enhancement (ADE). Despite that, many neutralizing antibodies have been identified against the DENV, which are thought to be useful in reducing dengue severity. Indeed, an antibody must be free from ADE for therapeutic application, as it is pretty common in dengue infection and escalates disease severity. Therefore, this review has described the critical characteristics of DENV and the potential immune targets in general. The primary emphasis is given to the envelope protein of DENV, where potential epitopes targeted for generating serotype-specific and cross-reactive antibodies have critically been described. In addition, a novel class of highly neutralizing antibodies targeted to the quaternary structure, similar to viral particles, has also been described. Lastly, we have discussed different aspects of the pathogenesis and ADE, which would provide significant insights into developing safe and effective antibody therapeutics and equivalent protein subunit vaccines.

Structure-guided vaccine design to focus antibody responses to neutralizing epitopes on dengue virus envelope protein

Abstract The four dengue virus (DV) serotypes are mosquito-borne flaviviruses responsible for dengue fever. Live-attenuated DV vaccines that are in human trials have had mixed results with efficacy for just one or two serotypes and an increased dengue risk in some vaccinated populations. DV recombinant envelope (E) proteins as subunit vaccines have had limited success, likely due to DV wild type E protein (WT rE) is mostly monomeric at physiological temperature. Hence, it loses the quaternary structure epitopes recognized by neutralizing human antibodies (Ab) on the native dimer. We previously showed that with targeted amino acid mutations, we can form DV thermostable dimers (SD rE) displaying native quaternary epitopes targeted by strongly neutralizing Ab. Here we report on studies to test if Ab response can be directed to these quaternary epitopes by using SD rE as vaccine antigens. Since fusion loop (FL) Ab can cause antibody dependent enhancement (ADE) that increases disease severity upon heterologous DV infection, we also tested SD rE with mutated FL. Mice were immunized with DV2 WT rE or SD rE variants to compare Ab properties induced by each antigen. We found that SD-vaccinated mice had higher DV2 functional Ab titer compared to WT-vaccinated. To map vaccine responses, we run neutralization assays with chimeric epitope transplant DV and sera depleted of Ab subpopulations. We use ADE assay to determine if stabilized E dimer and mutated FL reduces ADE compared to WT rE. Preliminary results indicate that WT-vaccinated mice neutralizing Ab bind to simple epitopes on rE monomers, while SD-vaccinated mice had mostly dimer-specific neutralizing Ab. Our results demonstrate the promise of structure-guided design for developing dengue subunit vaccines. NIH/NIAID U19 AI109784 R01AI107731 DOD/US Army Medical Research ACQ W81XWH1820034

Stability of Terminalia bellirica Extract and Its Combination Effect with Alpha-Mangostin in Inhibiting Dengue Virus Infection

Dengue virus (DENV) infection has been reported to be continuously increasing worldwide. Currently, there is no effective treatment specific to DENV infection, in addition, the efficiencies of the vaccines are not fully effective against all four circulating DENV serotypes. Therefore, the development of an anti-viral agent to combat DENV infection and lower the risk of disease progression is needed, especially in the endemic area. This study investigated the effect of Terminalia bellirica extract and its combination with alpha-mangostin (α-MG) in lowering the DENV serotype 2 infection in Vero cells and A549 lung adenocarcinoma cells. The phytochemical characterization of T. bellirica extract demonstrated that T. bellirica extract contained a total phenolic compound of 198.29 ± 15.95 mg gallic acid/g extract in which the gallic acid was the major bioactive compound, judged by HPLC. Treatment with 50 μg/mL of T. bellirica extract caused over 50% of DENV envelope protein reduction in Vero cells and showed no significant attenuation upon the six rounds of thermal stress exposures. At an equal concentration, the efficiency of T. bellirica extract in A549 cells was lower than that of Vero cells; however, combination with low-dose α-MG (0.5-2 μg/mL) showed to significantly improve the inhibitory activity of T. bellirica extract. This study demonstrated the great stability of T. bellirica extract to inhibit DENV infection and suggested a combination approach with α-MG offered protection against the DENV tissue tropism.

Development of novel antiviral peptides against dengue serotypes 1-4

Dengue infections pose a critical threat to public health worldwide. Since there are no clinically approved antiviral drugs to treat dengue infections caused by the four dengue virus (DENV) serotypes, there is an urgent need to develop effective antivirals. Peptides are promising antiviral candidates due to their specificity and non-toxic properties. The DENV envelope (E) protein was selected for the design of antiviral peptides due to its importance in receptor binding and viral fusion to the host cell membrane. Twelve novel peptides were designed to mimic regions containing critical amino acid residues of the DENV E protein required for interaction with the host. A total of four peptides were identified to exhibit potent inhibitory effects against at least three or all four DENV serotypes. Peptide 3 demonstrated all three modes of action: cell protection and inhibition of post-infection against all four DENV serotypes, whereas direct virus-inactivating effects were only observed against DENV-2, 3, and 4. Peptide 4 showed good direct virus-inactivating effects against DENV-2 (74.26%) as well as good inhibitions of DENV-1 (80.37%) and DENV-4 (72.22%) during the post-infection stage. Peptide 5 exhibited direct virus-inactivating effects against all four DENV serotypes, albeit at lower inhibition levels against DENV-1 and DENV-3. It also exhibited highly significant inhibition of DENV-4 (89.31%) during post-infection. Truncated peptide 5F which was derived from peptide 5 showed more significant inhibition of DENV-4 (91.58%) during post-infection and good direct virus-inactivating effects against DENV-2 (77.55%) at a lower concentration of 100 μM. Peptide 3 could be considered as the best antiviral candidate for pre- and post-infection treatments of DENV infections in regions with four circulating dengue serotypes. However, if the most predominant dengue serotype for a particular region could be identified, peptides with significantly high antiviral activities against that particular dengue serotype could serve as more suitable antiviral candidates. Thus, peptide 5F serves as a more suitable antiviral candidate for post-infection treatment against DENV-4.

Devising a multi epitope vaccine toward the dengue virus using the computational method in Bangladesh

Dengue is one of the major mosquito-borne diseases that still threaten humans and kill countless people. It is caused by a positive-stranded RNA virus that included the family of Flaviviridae. Dengue fever is an exquisite feverish viral disease dispatched by Aedes mosquitoes' sting, posing any one of the four dengue viral serotypes. This virus transmits through a vertical transmission way using a full unique system. Unfortunately, there is no still effective developed vaccine to eradicate this disease. Computational methods were used in this work to build and we suggest a multi-epitope vaccination for the dengue virus in Asia. This work employed different immunoinformatics and bioinformatics databases to predict powerful epitopes on the dengue virus envelope protein utilizing in silico techniques. We identified a total of 14 epitopes from the target envelope protein by evaluating their ability to induce both innate and acquired immunity via T and B lymphocyte-mediated reactions. Epitope conservation was taken into account because Dengue virus is an RNA virus, and all selected epitopes were 100% conserved. Antigenicity of the final multi-epitope vaccine component was 0.7055. Disulfide engineering was conducted at an area of high mobility to improve vaccine protein stability. In addition, codon adaptation and in silico cloning were used to guarantee that the planned subunit vaccine in E. coli was expressed at a greater level. Lastly, a molecular docking and simulation analysis was carried out for the vaccination protein and the TLR-4 receptor in order to assess the binding free energy and stability of the combination for this reason, the suggested in silico vaccine has to be tested for safety and immunogenicity in order to guarantee an active immunity against the Dengue virus.

A group of infection-enhancing and focus size-reducing monoclonal antibodies recognized an ‘a and c’ strands epitope in the pr domain of Dengue Virus prM

Partial cleavage of a dengue virus envelope protein, prM, by furin results in a mixture of extracellular particles with variable levels of maturation and infectivity. Partially mature particles can infect leukocytes via interaction between the prM-anti-prM antibody complex with Fcγ receptors. Known prM epitopes involved in antibody-mediated infection are localized to the pr domain. In this study, a group of murine anti-prM monoclonal antibodies with strong infection-enhancing activity was found to reduce the focus size of subsets of multiple dengue serotypes that they could enhance. By employing sets of overlapping peptides, four antibodies recognizing 2-mercaptoethanol-insensitive epitopes were mapped to a common tetrapeptide located distantly in the b-c loop and furin binding site. Substitution mutations of each, or both, of the tetrapeptides in virus-like particles, however, failed to reduce binding. Further mapping experiments were performed using immature virus-like particles with abolished furin binding site to minimize the differential influence of various pr substitutions on pr-M cleavage. Reduction of antibody binding was detected when single alanine substitutions were introduced into the ‘a’ strand and ‘c' strand of pr domain. These findings suggest that the pr ‘a and c' strands region is the major binding site of these unusual focus size-reducing anti-prM antibodies.

Identification of plant secondary metabolites as dengue envelope protein entry inhibitors through an in-silico approach

The entrance of the dengue virus to the host cell is mediated by its main envelope (E) protein. The crystal structure of E protein shows a hydrophobic pocket occupied by the detergent n-octyl-β-D-glucoside (βOG) lying in the Hinge region among domains I&II, which recognizes the hydrophobic ligand, opens and closes via a transition state in the beta-hairpin at the interface between two domains at low pH triggered conformational rearrangement necessary for fusion. We have identified fourteen plants that have been reported for anti-dengue activity. Though these plants are noted for anti-dengue activity, their molecular mechanisms are not fully explored. To know their targets, molecular docking experiments using Command Line Calculator (CLC) Drug Discovery Workbench Software have been performed against dengue virus envelope protein (DENV E) (PDB ID: 1OKE). The Glabranin and Hyperoxide have been showing docking scores (-52.89 and -51.27), nearing the standard n-Octyl-beta-D-glucopyranoside (-53.58). Therefore, Glabranin and Hyperoxide have been identified as High throughput virtual screening (HTVS) for combating DENV E protein.

Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019. Several studies reported that SARS-CoV-2 infections may produce false-positive reactions in dengue virus (DENV) serology tests and vice versa. However, it remains unclear whether SARS-CoV-2 and DENV cross-reactive antibodies provide cross-protection against each disease or promote disease severity. In this study, we confirmed that antibodies against the SARS-CoV-2 spike protein and its receptor-binding domain (S1-RBD) were significantly increased in dengue patients compared to normal controls. In addition, anti-S1-RBD IgG purified from S1-RBD hyperimmune rabbit sera could cross-react with both DENV envelope protein (E) and nonstructural protein 1 (NS1). The potential epitopes of DENV E and NS1 recognized by these antibodies were identified by a phage-displayed random peptide library. In addition, DENV infection and DENV NS1-induced endothelial hyperpermeability in vitro were inhibited in the presence of anti-S1-RBD IgG. Passive transfer anti-S1-RBD IgG into mice also reduced prolonged bleeding time and decreased NS1 seral level in DENV-infected mice. Lastly, COVID-19 patients’ sera showed neutralizing ability against dengue infection in vitro. Thus, our results suggest that the antigenic cross-reactivity between the SARS-CoV-2 S1-RBD and DENV can induce the production of anti-SARS-CoV-2 S1-RBD antibodies that cross-react with DENV which may hinder dengue pathogenesis.

Computational design of immunogenic peptide constructs comprising multiple human leukocyte antigen restricted dengue virus envelope epitopes.

Dengue virus (DENV) is endemic in 100 countries with the ability to impact nearly 50% of world population. DENV envelope (E) protein is responsible for viral attachment to host cells and has been target of various countermeasure development efforts. The current study focuses on a consensus computational approach to identify cross-reactive, immunogenic DENV-2 E peptides displaying promiscuity with a wide array of human leukocyte antigen (HLA) molecules. Four conserved peptides (FP-1, FP-2, FP-3 and FP-4) containing multiple CD8+ and CD4+ T cell epitopes were identified by employment of various immunoinformatics tools. FP-1, FP-2, FP-3 and FP-4 were estimated to bind with 227, 1787, 1008 and 834 HLA alleles, respectively. Root mean square deviation (RMSD) values obtained by molecular docking (CABS-Dock) with 20 HLA alleles (10 each of HLA classes I and II) resulted into comparable RMSD values of identified epitopes with native peptides, which represents the natural presentation of epitopes to HLA molecules. These peptides were also found to be part of previous experimentally validated immunogenic peptides. Further, a dengue immunogenic peptide construct was generated by linking the four peptides, an adjuvant and a 6× histidine tag. The construct showed strong binding and stability with Toll-like receptor. Collectively, these results provide strong evidence in the support of the immunogenic potential of the dengue immunogenic peptide construct.